^
    2d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative
    |
    methoxsalen (X-PACT)
    2ms
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Immunolight, LLC | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Sep 2025 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    methoxsalen (X-PACT)
    12ms
    Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=0, Available, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New trial
    |
    methoxsalen (X-PACT)
    over1year
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Immunolight, LLC | N=12 --> 20 | Trial completion date: Aug 2025 --> Mar 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    methoxsalen (X-PACT)
    almost2years
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Immunolight, LLC | Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    methoxsalen (X-PACT)
    over2years
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Immunolight, LLC | Trial primary completion date: Mar 2023 --> Mar 2024
    Trial primary completion date • Metastases
    |
    methoxsalen (X-PACT)